It has been shown that alterations in the balance of pro- and anti-apoptotic BCL2 proteins, including BAX downregulation, contribute to BH3 mimetic resistance in TP53-mutant AML [88]. The gene discussed is TP53; the disease is acute myeloid leukemia.